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Abstract
Atopic dermatitis is a chronic inflammatory skin disease. Multiple genetic and environmental factors are thought to be
responsible for susceptibility to AD. In this study, we collected 2,478 DNA samples including 209 AD patients and 729
control subjects from Taiwanese population and 513 AD patients and 1027 control subject from Japanese population for
sequencing and genotyping ORAI1. A total of 14 genetic variants including 3 novel single-nucleotide polymorphisms (SNPs)
in the ORAI1 gene were identified. Our results indicated that a non-synonymous SNP (rs3741596, Ser218Gly) associated with
the susceptibility of AD in the Japanese population but not in the Taiwanese population. However, there is another SNP of
ORAI1 (rs3741595) associated with the risk of AD in the Taiwanese population but not in the Japanese population. Taken
together, our results indicated that genetic polymorphisms of ORAI1 are very likely to be involved in the susceptibility of AD.
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Introduction
Atopic dermatitis (AD) or childhood eczema is a chronic
relapsing inflammatory skin disease [1] that usually associated with
a family history of atopic disorders such as allergic rhinitis and
bronchial asthma [2,3,4]. There has been a dramatic increase in
the prevalence of AD in the last decade. Although the
pathogenesis of AD remains elusive, multiple genetic and
environmental factors are thought to contribute to the disease
onset [2,3,4]. Genes associated with skin-barrier formation and
adaptive immunity have been implicated in the development of
AD. For example, filaggrin (FLG) is essential for the maintenance
of the skin-barrier function. Genetic mutations in FLG are
significantly associated with the risk of AD and elevated
immunoglobulin E (IgE) levels [5]. In addition, single nucleotide
polymorphisms (SNPs) in Toll-like receptors (TLRs), ST2, IL-3,
IL-4, IL-5, IL12RB1, and IL-13 have been shown to be associated
with the pathogenesis of AD [6,7,8,9,10,11,12]. The results from a
genome-wide association study (GWAS) have indicated the
complex involvement of multiple loci in the susceptibility of
human AD [13].
Despite all the knowledge, the treatment of severe AD remains a
challenge. Clinical trials have indicated that cyclosporine is an
effective treatment option in children with AD. Short-term
treatment with cyclosporine has shown to alleviate disease activity
[14]. Cyclosporine, an immunosuppressant, functions as a
phosphatase inhibitor that prevents the translocation of calcium-
dependent transcription factor—nuclear factor of activated T cells
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29387(NFAT). The influx of calcium through store-operated calcium
(SOC) channels is one of the major pathways to increase the
intracellular calcium concentration in non-excitable cells such as
the mast cells and T lymphocytes [15]. In mast cells, short-term
SOC influx has been shown to result in the secretion of
inflammatory molecules such as arachidonic acids and leukotriene
C4 [16,17]. In T lymphocytes, the nuclear translocation of NFAT
could be driven by the SOC-mediated calcineurin signaling
pathway in order to control immune responses [18]. The mole-
cular components of the SOC channels were first identified in
patients with severe combined immune deficiency (SCID) syn-
drome [19]. ORAI1 gen encoding Orai1 protein is one of the
major proteins of SOC channels. A point mutation created in the
ORAI1 gene resulted in the reduction of calcium influx through
the SOC channels and dysfunction of the immune system. ORAI1-
knockout mice exhibited defective mast cells and attenuated
cytokine release [20].
In our study, we first conducted LD (linkage disequilibrium)
mapping of the ORAI1 gene, performed a case-control
association study and showed a haplotype analysis. We then
tested the correlation between the ORAI1 genetic polymor-
phisms and the expression level of the ORAI1 transcript. Our
results support a functional role of ORAI1 polymorphisms in the
s u s c e p t i b i l i t yo fh u m a nA Di nb o t hJ a p a n e s ea n dT a i w a n e s e
population.
Materials and Methods
Subjects
A total of 513 atopic dermatitis patients were recruited in
Takao Hospital and the University of Tokyo. All subjects with
atopic dermatitis were diagnosed according to the criteria of
Hannifin and Rajka [21]. There are four major criteria,
including pruritus, chronic or relapsing dermatitis, dermatitis
affecting flexural surfaces in adults, and a personal or family
history of cutaneous or respiratory atopy. There are 23 minor
criteria, such as hypopigmented patch, infraorbital darkening,
cheilitis, hyperlinerized palm, and elevated IgE, etc. To be
included, the patients had to meet three major criteria plus at
least one minor criterion or two major criteria plus at least three
minor criteria. Japanese subjects with AD were recruited from
several hospitals and diagnosed according to the criteria of
Hanifin and Rajka by dermatologists. A total of 839 adult control
individuals who had no history of bronchial asthma, allergic
rhinitis and atopic dermatitis were recruited by detailed doctors’
interviews. A total of 188 healthy individuals who had no history
of atopic dermatitis based on a questionnaire were recruited in
Fukui University (3).
Information of these participants is provided in Table S1. All
individuals were unrelated Japanese and gave written informed
consent to participate in the study according to the rules of the
process committee at the Center for Genomic Medicine, The
Institute of Physical and Chemical Research (RIKEN).
A total of 209 AD patients were recruited from a
dermatological clinic at Kaohsiung Medical University hospital
and National Taiwan University hospital in Taiwan from
January 1st to December 15th in 2008. A diagnosis of AD
patients was also based on criteria proposed by Hanifin and
Rajka [21]. Information of these participants is provided in
Table S2. We took a medical history and performed physical
examinations and blood biochemistry exams to exclude other
diseases causing pruritus, such as contact dermatitis, asteatotic
dermatitis, and metabolic diseases. Suspected cases were
biopsied to exclude other mimicking cutaneous diseases,
including cutaneous T cell lymphoma. Patients were excluded
if they had received any topical treatments for at least 2 weeks
or systemic treatment for 2 months prior to the study. Patients
were excluded if they had actives k i nd i s e a s e so t h e rt h a nA D ,
including HIV infection and cancers of any origin. Patients
visiting the same hospital in the Department of Preventive
Medicine for medical diseases other than atopic diseases were
referred to the Department of Dermatology were hospital-based
controls. They were excluded if they had active skin diseases,
past history of AD, allergic asthma, allergic rhinitis, allergic
Table 1. Locations and allele frequencies of polymorphisms in ORAI1.
SNP
a Location Amino acid Allele frequency(%) NCBI
b
Marker 1 2979G/A 59 flanking region 2
Marker 2 2410G/A 59 flanking region 2 rs116376569
Marker 3 2244GTCCAGGCCCCGGGG61/625 9 flanking region 4
Marker 4
c 14542C/T exon2 I182I 33 rs3741595
Marker 5
c 14648A/G exon2 S218G 17 rs3741596
Marker 6 14701T/C exon2 A235A 17 rs3741597
Marker 7 14782T/C exon2 V262V 17 rs3825174
Marker 8
c 14794C/T exon2 T266T 33 rs3825175
Marker 9 14952T/A 39 UTR 17 rs11548651
Marker 10 14988C/T 39 UTR 17 rs76753792
Marker 11
c 1502A/G 39 UTR 33 rs712853
Marker 12 15036insT 39 UTR 33 rs35558190
Marker 13 15123T/C 39 UTR 2
Marker 14 15375A/G 39 flanking region 17 rs74808898
aNumbering according to the genomic sequence of ORAI1 (AC140062.11).
Position 1 is the A of the initiation codon.
bNCBI, Number from the dbSNP of NCBI (http://www.ncbi.nlm.nih.gov/SNP/).
cSNPs were genotyped in both Taiwanese and Japanese population.
doi:10.1371/journal.pone.0029387.t001
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LOD (upper) and r
2 (lower) for all combinations of SNP pairs are shown.
doi:10.1371/journal.pone.0029387.g001
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taking oral corticosteroids. A board-certified dermatologist took
a medical history, examined the whole surface the body, and
assigned a SCORAD severity index score for each subject.
Venous peripheral blood was drawn and the serum was stored
at 270uCu n t i la s s a y e d .I g El e v e l sf r o mA Dp a t i e n t sw e r e
measured in a College of American Pathologists (CAP)
accredited laboratory in the same hospital. The study was
approved by the Institutional Review Board of the Hospital. All
clinical assessments and specimen collections were conducted
according to Declaration of Helsinki principles. Each partici-
pant signed an informed written consent form before entering
the study. Patients or controls who did not sign the inform
consent were excluded.
Selection of human ORAI1 polymorphisms for
genotyping
Genomic DNA was prepared from peripheral blood samples
using standard protocols. To identify SNPs in the human ORAI1
gene, we sequenced all exons, including a minimum of 200 bases of
the flanking intronic sequence, 2 kb of the 59 flanking region, and a
2 kbcontinuous39flankingregionofthelastexonexceptforregions
with interspersed repeats from 24 subjects as described in Japanese
population. Pairwise LD was calculated as D9/LOD and r
2 and the
Tag SNPs were selected among 10SNPs with a frequency ofgreater
than 10% by using the Haploview 4.2program (http://www.broad.
mit.edu/mpg/haploview/). Genotyping of SNPs was performed by
the TaqMan allele-specific amplification (TaqMan-ASA) method
(Applied Biosystems, Foster City, CA).
Figure 2. A graphical overview of ORAI1 gene polymorphisms identified in in the Japanese population (upper). A graphical overview of
tSNPs of ORAI1 gene selected for genotyping in the Taiwanese population.
doi:10.1371/journal.pone.0029387.g002
Table 2. Genotype counts for ORAI1 and atopic dermatitis susceptibility in Japanese and Taiwanese population.
Japanese (case-control association analysis) Taiwanese (case-control association analysis)
Genotype
a Allele*2 Genogype Allele*2
db SNP ID
Allele
1/2 Subjects 1/1 1/2 2/2
Frequency
of allele 2 P
a OR (95% c.i.) 1/1 1/2 2/2
Frequency
of allele 2 P OR (95% c.i.)
rs12320939 G/T AD 50 90 67 0.54 0.050 1.25 (1.00–1.55)
Control 184 341 165 0.49
rs6486795 T/C AD 59 93 47 0.47 0.0004 1.50 (1.20–1.88)
Control 277 320 98 0.37
rs3741595 C/T AD 323 160 25 0.21 0.275 0.90 (0.75–1.08) 83 93 31 0.37 0.0001 1.59 (1.27–2.01)
Control 622 343 58 0.22 370 275 53 0.27
rs3741596 A/G AD 315 177 19 0.21 0.002 1.36 (1.12–1.64)
Control 717 283 27 0.16
rs3825175 C/T AD 197 243 71 0.38 0.245 0.91 (0.78–1.06) 89 81 37 0.37 0.187 0.86 (0.69–1.08)
Control 379 476 171 0.40 239 346 114 0.41
rs712853 G/A AD 165 266 80 0.42 0.027 1.19 (1.02–1.38) 26 71 109 0.70 0.035 1.29 (1.02–1.64)
Control 397 479 144 0.38 97 303 301 0.65
aP values represent the Cochran-Armitage trend P for case-control comparisons.
doi:10.1371/journal.pone.0029387.t002
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in 10 subjects, however, none of SNP was found. We further choose
five ORAI1 tagging SNPs (rs12320939, rs6486795, rs3741595,
rs3825175 and rs712853) with a minor allele frequency .10% in
the Han Chinese population were selected from the HapMap
database (http://www.hapmap.org). Genotyping was performed
using the TaqMan Allelic Discrimination Assay (Applied Biosys-
tems, Foster city, CA, USA). The polymerase chain reaction (PCR)
was carried out using the ABI7900 Thermal Cycler. After PCR,
fluorescence from reaction products was measured and analyzed
using the System SDS software version 1.2.3.
Real-time quantitative RT-PCR
Total RNA from normal human tissues was purchased from
Clontech (Mountain View, CA). Each RNA was reverse
transcribed with Superscript III reverse transcriptase and oligo
dT primers (Invitrogen, Carlsbad, CA). The expression of ORAI1
transcripts was determined by real-time quantitative reverse
transcription polymerase chain reaction (RT-PCR) using SYBR
Premix Ex Taq (Takara, Shiga, Japan) with specific primers (59-
ACCTCGGCTCTGCTCTCC -39 and 59- GATCATGAGCG-
CAAACAGG -39). In all experiments, the amounts of cDNA were
standardized by quantification of the housekeeping gene glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical analysis
We tested agreement with Hardy-Weinberg Equilibrium using a
x
2 goodness-of-fit test at each locus in both populations. In
Japanese population, we then compared differences in genotype
frequencies of the polymorphisms between case and control
subjects by the Cochran-Armitage trend test, and calculated odds
ratios (ORs) with 95 percent confidence intervals (95% CI). We
applied Bonferroni correction; the multiplication of the P values by
four, the number of tag SNPs. In the association study, P values
of less than 0.05 were considered to be statistically significant.
Haplotype frequencies for three loci were estimated, and hap-
lotype association tests were performed using Haploview 4.2. Total
IgE levels and expression levels of ORAI1 transcripts between
genotypicgroupsweretestedwiththe Jonckheere-Terpstratest.Chi-
square test was then used to compare differences in allele fre-
quencies and genotype distribution of the polymorphisms between
AD and controls.
Results
Association of ORAI1 SNPs with susceptibility to atopic
dermatitis
After extensive examination of ORAI1 by direct sequencing, we
identified 14 polymorphisms (three SNPs in promoter region and
five SNPs within the transcript) (Table 1). Eight polymorphisms
were contained in the available public databases, NCBI dbSNP
(http://www.ncbi.nlm.nih.gov/SNP/). We calculated pairwise
linkage disequilibrium (LD) as r
2 and selected four tag SNPs with
a minor allele frequency (MAF) of .10% using the Haploview 4.2
program (http://www.broad.mit.edu/mpg/haploview/). The four
tag SNPs captured 10 of the 10 alleles with a mean r
2 of 0.98
(r
2.0.76) (Figure 1 and Table S3). The locations of these four
SNPs are shown in Figure 2 (upper). In Taiwanese population, five
ORAI1 tagging SNPs with a minor allele frequency .10% in the
Han Chinese population were selected from the HapMap
database (http://www.hapmap.org). A graphical overview of the
genotyped polymorphism is shown in Figure 2 (Lower).
We next carried out case-control association studies of the four
and five SNPs in the 1540 Japanese subjects and 938 Taiwanese
subjects. The control genotypes did not deviate from Hardy-
Weinberg equilibrium. As shown in Table 2, a nonsynonymous
ORAI1 SNP (rs3741596, Ser218Gly) showed significant associa-
tions with susceptibility to atopic dermatitis (P=0.002, OR=1.36,
95% CI 1.12–1.64) by the Cochran-Armitage trend test in
Japanese population. Other variants did not show a significant
association after Bonferroni correction. In Taiwanese population,
rs6486795 and rs3741595 were significantly associated with
susceptibility to atopic dermatitis under the dominant and allelic
models.
Figure 3. ORAI1 gene LD and haplotype block structure in AD.
The number on the cell is the LOD score of D9.
doi:10.1371/journal.pone.0029387.g003
Table 3. Haplotype frequency of four SNPs in ORAI1 in Japanese population.
n Frequency Odds ratio
rs3741595 rs3741596 rs3825175 rs712853 AD Control AD Control P value (95% c.i.)
Haplotype 1 C A T G 386 819 0.38 0.40
Haplotype 2 T A C G 212 459 0.21 0.22
Haplotype 3 C A C A 211 435 0.20 0.21
Haplotype 4 C G C A 216 337 0.21 0.16 0.0017 1.36 (1.12–1.64)
1026 2050 1.00 1.00
doi:10.1371/journal.pone.0029387.t003
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disease occurrence of atopic dermatitis
To further identify the effects of Haplotypes of ORAI1 to atopic
dermatitis, we constructed the haplotypes of the three SNPs to
estimate the frequency of each haplotype in controls in the
Japanese population (Table 3). Three common haplotypes were
identified in the Japanese population. Haplotype C-G-C-A
(rs3741595, rs3741596, rs3825175, and rs712853) of ORAI1 was
significantly associated with atopic dermatitis. A P value of 0.0017
was obtained by using the Haploview 4.2 program. In the
Taiwanese population, the haplotype block structure of ORAI1 was
shown in Figure 3. Among five haplotypes, subjects with T-C-T-C
haplotype (rs12320939, rs6486795, rs3741595 and rs3825175)
have a significant risk to AD (OR=1.54, 95% CI=1.18–2.01,
P=0.0014) (Table 4).
Expression of ORAI1 mRNA in skin, immune tissues
To investigate the ORAI1 mRNA expression in various human
tissues, we conducted real-time quantitative RT-PCR. As shown in
Figure 4, ORAI1 mRNA was expressed abundantly in all tissues
examined, especially in the tissues of lung, spleen, and skin.
rs3741597 is associated with the expression level of the
ORAI1 transcript
We next assessed whether the rs3741597 genotype correlated
with the mRNA levels of ORAI1 transcript (NM_032790). The
ORAI1 mRNA expression data for the EBV-transformed lympho-
blastoid cell lines from 42 JPT HapMap subjects were analyzed by
the Jonckheere-Terpstra trend test. As shown in Figure 5, the
expression level of transcripts of NM_032790 was positively
correlated with the rs3741597 genotype (P=0.040). These results
suggested that rs3741597 or other SNPs, 14648A/G (rs3741596),
14782T/C (rs3825174), 14952T/A (rs11548651), 14988C/T
(rs76753792), and 15375A/G (rs74808898), in strong linkage
disequilibrium with rs3741597 might influence susceptibility to
atopic dermatitis through higher expression of an ORAI1 transcript.
Discussion
We screened the polymorphisms of ORAI1 and performed a
case-control association study and a haplotype analysis. A total of
14 genetic variants was identified from Japanese population, 3
SNPs are novel. Our results showed a significant association
between AD and a non-synonymous SNP (rs3741596, Ser218Gly)
Table 4. Haplotype frequency of four SNPs in ORAI1 in Taiwanese population.
n Frequency Odds ratio
rs12320939 rs6486795 rs3741595 rs3825175 AD Control AD Control P value (95% c.i.)
Haplotype 1 T C T C 148 370 0.38 0.27 0.0014 1.54 (1.18–2.01)
Haplotype 2 T C C C 36 130 0.09 0.10
Haplotype 3 T T C C 33 154 0.08 0.11
Haplotype 4 G T C C 30 142 0.08 0.10
Haplotype 5 G T C T 143 550 0.36 0.41
390 1346 0.99 0.99
If the frequencies less than 1% were excluded.
doi:10.1371/journal.pone.0029387.t004
Figure 4. Expression of ORAI1 mRNA in different tissues. Quantities of total RNA extracted from normal human tissues were determined by
real-time quantitative reverse transcription polymerase chain reaction (RT-PCR). The results were normalized to GAPDH transcripts.
doi:10.1371/journal.pone.0029387.g004
ORAI1 Genetic Polymorphisms and Atopic Dermatitis
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29387in the human ORAI1 gene in the Japanese population. rs3741596
was genotyped in the Taiwanese population, however, the MAFs
of this SNP is less than 1% which is different from the allele
frequency of Japanese population (data not shown). In addition,
rs3741595 of ORAI1 is associated with the risk of AD in the
Taiwanese population but not in the Japanese population. We also
performed I
2 index to assess heterogeneity on three SNPs which
were genotyped in both Taiwan and Japan. The I
2 indexes of
rs3825175 and rs712853 showed no heterogeneity on these locus.
The heterogeneity only occurred on rs3741595 (I
2 Index=93%)
We attribute this to the different genetic backgrounds in the
populations, due to variation in allele frequencies, population
admixture, heterogeneity of the phenotype between populations.
The rs3741597 genotype correlated with the mRNA levels of
the ORAI1 transcript. Another three SNPs (14952T/A, 14988C/
T, and 15375A/G) located in the 39 flanking region, which are in
strong LD with rs3741597, may influence higher expression of an
ORAI1 transcript. MicroRNAs (miRNA) are small non-coding
RNAs that control gene expression by preferentially binding to the
39-untranslated regions (39-UTR) of the target genes [22].
Therefore, further functional analysis of the 39-UTR of the ORAI1
gene should be conducted in order to clarify the mechanism
underlying this susceptibility.
Several diseases have been linked to the ORAI1-mediated
calcium influx. Feske et al. identified a mutation in the Orai1 from
SCID patients. This missense mutation caused a reduction in the
SOC influx and a decrease in immune response [19]. Studies from
the Orai1-knockout mice have shown an important role of this
gene in the activation of inflammatory reactions in mast cells
[20,23]. To study the role of ORAI1, we analyzed the tissue
distribution of ORAI1. The highest expression of ORAI1 was
found in the spleen, an organ involved in immune function. The
tissue distribution of ORAI1 in our study revealed the potential
importance of ORAI1 in the regulation of immune system—a
finding consistent with that reported previously. In addition, the
expression of ORAI1 was found to be higher in the proliferative
vascular smooth muscle cells [24]. Furthermore, results obtained
from ORAI1 knockdown cells indicated a reduction of cell
proliferation in both endothelial and breast cancer cells [25,26].
Studies using keratinocytes have shown that calcium is an
important regulator of cell proliferation and differentiation [27].
Dysregulated apoptosis in keratinocytes contributes to the progress
of AD [28]. Hence, genetic polymorphisms may result in the
changes of gene expression level of ORAI1 that further contribute
to the dysregulated growth in keratinocytes, leading to a defective
skin-barrier formation. Cell-based physiological studies in the
keratinocytes are required to identify the role of ORAI1 in AD.
STIM1 and ORAI1 are the two major components in the
regulation of calcium entry through store-operated calcium
channels. Co-expression of STIM1 and Orai1/CRACM1 results
in the amplification of store-operated Ca
2+ influx signals [1,29,30].
The SOC entry pathway is influenced by ORAI1 or STIM1
knockdown [31,32]. Importantly, the overexpression of orai1 also
causes the attenuation of store-operated Ca
2+ influx [33]. Two
possible mechanisms were proposed. The oligomers formed by the
overexpressed ORAI1 may lose sensitivity to the signals released
from calcium store [34]. Soboloff et al. suggested that the coupling
stoichiometry between Orai1 and STIM1 is not unity, therefore,
overexpression of Orai1 may influence the functional compositions
of SOC [30]. Combined the findings from other groups [34], our
results propose that the genetic polymorphisms in the 39-UTR of
the ORAI1 gene may change the expression level of Orai1, which,
in turn, may cause dysfunction of calcium channels and immune
responses. However, the coupling stoichiometry between the
different expression levels of ORAI1 should also be further
considered.
Previous studies have revealed the significant association
between genetic polymorphisms of ORAI1 and inflammatory
diseases such as ankylosing spondylitis and calcium nephrolithiasis
[35,36]. In this study, we identified 14 genetic variants including 3
novel SNPs in the ORAI1 gene. In a total of 2,478 subjects (938
Taiwanese and 1540 Japanese), our results indicated that different
genetic polymorphisms of ORAI1 are associated with AD
susceptibility in the Japanese, and Taiwanese populations. This
is the first report to state the relationship between the genetic
polymorphisms of ORAI1 and allergic diseases. Given the
polygenic nature of allergic diseases such as AD, the susceptibility
gene ORAI1 could provide a new clue in the pathogenesis of AD.
The prevalence of atopic dermatitis in Taiwan is around 6.7%,
therefore, this study should reach a power level of 0.97 (case 209;
control 729). Although further replication studies in larger
Taiwanese population is needed, it is likely to variants in the
ORAI1 gene play a role in susceptibility to AD in both Japanese
and Taiwanese populations. Further study on the relationship
between the genotype of ORAI1 and the downstream functional
relevance during dermal inflammation should be conducted in
order to understand the etiology of AD.
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